Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (ISRCTN63918057) titled 'Daridorexant for Alzheimer's disease prevention' on Oct. 7.
Study Type: Interventional
Study Design:
Single-site double-blind randomized placebo-controlled interventional study (Prevention)
Primary Sponsor: Douglas Mental Health University Institute
Condition:
Prevention of Alzheimers disease in participants without Alzheimers disease dementia, experiencing sleep problems or not
Mental and Behavioural Disorders
Intervention:
240 participants will be randomized (1:1). There are 2 arms. One experimental arm (daridorexant 50 mg) and one placebo arm. Study drug (daridorexant 50 mg or placebo) will be taken ora...